Vistagen Therapeutics (VTGN) Interest Expenses (2010 - 2026)
Vistagen Therapeutics (VTGN) posted Interest Expenses of $5000.0 for Q1 2026, down 99.84% sequentially from $3.2 million in Q3 2025, and down 99.38% YoY from $800000.0 in Q1 2025.
Vistagen Therapeutics (VTGN) Interest Expenses (2010 - 2026) Analysis & Trends
Vistagen Therapeutics has reported Interest Expenses for 17 years, with the latest figure at $5000.0 in Q1 2026.
- Quarterly Interest Expenses fell 99.38% year-over-year to $5000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $805000.0 (down 22.95% YoY) and the FY2026 annual result came in at $93.4 million, up 20.19% from the prior year.
- Interest Expenses eased to $5000.0 in Q1 2026 per VTGN's latest filing, from $3.2 million in the prior quarter.
- Over five years, Interest Expenses peaked at $60.5 million in Q1 2024 and troughed at $5000.0 in Q1 2026.
- A 5-year average of $5.1 million and a median of $450050.0 in 2023 frame the typical range for Interest Expenses.
- The sharpest annual moves came in 2024 and 2026: Interest Expenses surged 24622.63% in 2024, then tumbled 99.38% in 2026.
- Over 5 years, Interest Expenses stood at $590100.0 in 2022, then slipped by 18.98% to $478100.0 in 2023, then tumbled by 96.86% to $15000.0 in 2024, then soared by 20900.0% to $3.2 million in 2025, then tumbled by 99.84% to $5000.0 in 2026.
- According to Business Quant data, Interest Expenses over the past three periods registered $5000.0, $3.2 million, and $62000.0 for Q1 2026, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 82.05 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -4.89 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 20.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 93.62 Mn |
| 10 | Vistagen Therapeutics | 10.49 Mn | 10.49 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5,000.00 |
| Mar 31, 2026 | 5,000.00 |
| Sep 30, 2025 | 3.15 Mn |
| Sep 30, 2025 | 3.15 Mn |
| Jun 30, 2025 | 62,000.00 |
| Jun 30, 2025 | 62,000.00 |
| Mar 31, 2025 | 800,000.00 |
| Mar 31, 2025 | 800,000.00 |
| Dec 31, 2024 | 15,000.00 |
| Dec 31, 2024 | 15,000.00 |
| Sep 30, 2024 | 13,000.00 |
| Sep 30, 2024 | 13,000.00 |
| Jun 30, 2024 | 422,000.00 |
| Jun 30, 2024 | 422,000.00 |
| Mar 31, 2024 | 60.52 Mn |
| Mar 31, 2024 | 60.52 Mn |
| Jun 30, 2023 | 478,100.00 |
| Jun 30, 2023 | 478,100.00 |
| Mar 31, 2023 | 244,800.00 |
| Mar 31, 2023 | 244,800.00 |